Publications by authors named "Diarmuid Moran"

Claim this Profile
A
Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW.
Steven P Stratton, Lizhen Pang, Judith Pugh, Margarita Kouzova, Drew Baldwin, Sean Moran, Diarmuid Moran

Mod Pathol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
Kohei Shitara, Manish A Shah, Florian Lordick, Yung-Jue Bang, David Ilson, Diarmuid Moran

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Kohei Shitara, Rui-Hua Xu, Jaffer A Ajani, Diarmuid Moran, Abraham Guerrero

Gastric Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
Kohei Shitara, Manish A Shah, Florian Lordick, Eric Van Cutsem, David H Ilson, Diarmuid Moran

N Engl J Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma.
Rebecca Waters, Matheus Sewastjanow-Silva, Kohei Yamashita, Ahmed Abdelhakeem, Kenneth K Iwata, Diarmuid Moran

JCO Precis Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Samuel J Klempner, Keun-Wook Lee, Kohei Shitara, Jean-Phillippe Metges, Sara Lonardi, Diarmuid Moran

Clin Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Manish A Shah, Kohei Shitara, Jaffer A Ajani, Yung-Jue Bang, Peter Enzinger, Diarmuid Moran

Nat Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Diarmuid Moran

Lancet· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
Noboru Yamamoto, Baek-Yeol Ryoo, Bhumsuk Keam, Masatoshi Kudo, Chia-Chi Lin, Diarmuid Moran

Invest New Drugs· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The transobturator suburethral sling: a safe and effective option for all degrees of post prostatectomy urinary incontinence.
John F Sullivan, Paul N Stassen, Diarmuid Moran, Eva M Bolton, Lisa G Smyth

Can J Urol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.
Helena A Yu, Alexander Spira, Leora Horn, Jared Weiss, Howard West, Diarmuid Moran

Clin Cancer Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
Christopher A Hamm, Diarmuid Moran, Kakuturu Rao, Patricia B Trusk, Karen Pry

Mol Cancer Ther· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Kimberly R Doherty, Dominique R Talbert, Patricia B Trusk, Diarmuid M Moran, Scott A Shell

Toxicol Appl Pharmacol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
Dominique R Talbert, Kimberly R Doherty, Patricia B Trusk, Diarmuid M Moran, Scott A Shell

Toxicol Sci· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
Diarmuid M Moran, Patricia B Trusk, Karen Pry, Keren Paz, David Sidransky

Mol Cancer Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors.
Michael J Breen, Diarmuid M Moran, Wenzhe Liu, Xiaoke Huang, Calvin P H Vary

PLoS One· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Kimberly R Doherty, Robert L Wappel, Dominique R Talbert, Patricia B Trusk, Diarmuid M Moran

Toxicol Appl Pharmacol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells.
Diarmuid M Moran, Carl G Maki

Mol Cancer Ther· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes.
Diarmuid M Moran, Hong Shen, Carl G Maki

BMC Cell Biol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells.
Hong Shen, Diarmuid M Moran, Carl G Maki

Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microencapsulation of engineered cells to deliver sustained high circulating levels of interleukin-6 to study hepatocellular carcinoma progression.
Diarmuid M Moran, Leonidas G Koniaris, Elizabeth M Jablonski, Paul A Cahill, Craig R Halberstadt

Cell Transplant· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular pathogenesis of hepatocellular carcinoma.
Iain H McKillop, Diarmuid M Moran, Xiaoling Jin, Leonidas G Koniaris

J Surg Res· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma.
Diarmuid M Moran, Nicholas Mayes, Leonidas G Koniaris, Paul A Cahill, Iain H McKillop

Liver Int· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis